Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
01 11월 2023 - 9:00PM
Business Wire
Conference Call Scheduled for Wednesday,
November 8, 2023 at 4:30 p.m. ET
Revance Therapeutics, Inc. (RVNC) today announced that the
company will release third quarter 2023 financial results on
Wednesday, November 8, 2023, after the close of market. Revance
will host a corresponding conference call and a live webcast at
1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results
and provide a corporate update.
Individuals interested in listening to the conference call may
do so by dialing (833) 470-1428 for U.S. and Canadian callers, and
reference conference ID 509643 or from the webcast link in the
investor relations section of the company's website at:
www.revance.com.
A webcast replay will be available beginning November 8, 2023,
at 4.30 p.m. PT / 7.30 p.m. ET to February 8, 2024 at 4.30 p.m. PT
/ 7.30 p.m. ET. To access the replay, please register via the
webcast link on the events page. The webcast will be available in
the investor relations section on the company's website for 90 days
following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
enhance patient outcomes and physician experiences. Revance’s
portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for
injection and the RHA® Collection of dermal fillers in the U.S.
Revance has also partnered with Viatris Inc. to develop a
biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun
Pharmaceutical to commercialize DAXXIFY® in China.
Revance is headquartered in Nashville, Tenn., with additional
office locations in Newark and Irvine, Calif. Learn more at
www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com,
www.hcp.DAXXIFYTherapy.com, or connect with us on LinkedIn.
“Revance” and the Revance logo, and DAXXIFY® are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101838360/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com Media
Revance Therapeutics, Inc.: Sara J. Fahy, 949-887-4476
sfahy@revance.com
Revance Therapeutics (NASDAQ:RVNC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Revance Therapeutics (NASDAQ:RVNC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
